Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284784 · ClinicalTrials.gov registry record · Phase 2
A Study of Buntanetap in Participants With PD
A Phase 2 study of Parkinsons Disease (PD) and Deep Brain Stimulation, sponsored by Annovis Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT07284784 is a Phase 2 study of Parkinsons Disease (PD) and Deep Brain Stimulation that is actively recruiting participants, run by Annovis Bio. The registered enrollment target is 500 participants, above the 93-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (438% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT07284784, a Phase 2 study of Parkinsons Disease (PD) and Deep Brain Stimulation, is actively recruiting participants, sponsored by Annovis Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Conditions Studied
Interventions
- DRUG buntanetap/posiphen
Study Locations (20)
Florida
- First Choice Neurology - Aventura Neurologic Associates - Aventura
- Arrow Clinical Trials - Daytona Beach
- Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU - DeLand
- Renstar Medical Research - Ocala
- University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di - Tampa
- Conquest Research - Winter Park
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research - Sun City
California
- Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office - Fountain Valley
Colorado
- Cenexel Rocky Mountain Clinical Research - Englewood
Connecticut
- New England Institute for Clinical Research (Ki Health Partners) - Stamford
Georgia
- iResearch Atlanta - Decatur
Indiana
- Josephson Wallack Munshower Neurology, P.C. - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07284784
The ClinicalTrials.gov registry entry for NCT07284784 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 93-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (438% higher). The listed sponsor is Annovis Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which buntanetap/posiphen is the first listed.
NCT07284784 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT07284784 about?
NCT07284784 is a clinical study titled "A Study of Buntanetap in Participants With PD". This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical tri...
What is the current status of trial NCT07284784?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2026-01-09. Estimated completion is 2029-11.
What conditions does trial NCT07284784 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD), Deep Brain Stimulation.
What interventions are being tested in trial NCT07284784?
The interventions under investigation include: buntanetap/posiphen (DRUG).
Who is sponsoring clinical trial NCT07284784?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284784 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
RECRUITING · Phase 2
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.